Eli Lilly is reportedly in advanced negotiations to acquire the Boston-based biotech company Kelonia Therapeutics for a staggering sum exceeding $2 billion. According to sources, an announcement could come as soon as Monday, although there remains a chance that the talks may not culminate in a finalized deal.
The acquisition, if completed, may also entail milestone-based payments contingent on Kelonia successfully achieving specific development objectives. Following this news, Eli Lilly’s stock (LLY) witnessed a rise of approximately 2.55%.
Kelonia Therapeutics is a clinical-stage biotech firm dedicated to developing innovative CAR-T cell therapies—a treatment that reprograms a patient’s immune cells to identify and eliminate cancer cells. The company’s primary focus revolves around multiple myeloma, a form of blood cancer. Their distinct approach aims to simplify CAR-T treatment by eliminating the necessity for chemotherapy and the complex manufacturing processes typically associated with these therapies.
This simplification could substantially alleviate logistical challenges that have long hindered the CAR-T treatment landscape. So far, Kelonia has successfully raised close to $60 million in funding and was valued at just over $100 million in 2022—making the proposed acquisition price significantly higher.
Eli Lilly has already established a presence in oncology with a portfolio that includes effective treatments like Jaypirca and the breast cancer drug Verzenio, alongside other promising pipeline candidates. The acquisition of Kelonia would enhance Lilly’s footprint in the fast-growing blood cancer treatment segment.
The potential buyout is indicative of a broader strategy by Eli Lilly to expand its therapeutic offerings, particularly beyond its standout weight-loss drug, Zepbound, and diabetes medication, Mounjaro. Earlier this year, the company announced plans to acquire Orna Therapeutics for up to $2.4 billion, and if successful, the Kelonia deal would represent another substantial investment in a short frame of time.
Lilly has signaled its ambition to diversify its portfolio, signaling interest in areas such as inflammatory bowel disease, eye conditions, cancer, and gene-editing technologies. Their foray into CAR-T therapies aligns well with this goal, as these treatments have demonstrated strong effectiveness in addressing blood cancers despite ongoing challenges regarding manufacturing complexity and costs.
What makes Kelonia’s approach particularly appealing is its potential to yield results with fewer logistical hurdles—a competitive advantage that could justify the hefty acquisition cost. While Eli Lilly has yet to confirm the deal, the Wall Street Journal has reported that negotiations remain fluid, with the chance for the deal to be called off before an official announcement.
As the situation evolves, the market remains attentive, with LLY stock enjoying positive movement on the news of this possible acquisition.
